Patients

Preclinical Phase 1 Phase 2 Phase 2b Phase 3
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase complete
Phase 3 Phase in progress
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 2b Phase in progress
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 2b Phase not started
Phase 3 Phase not started

Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus

To learn more about each of our ongoing studies, please click on one of the below links.